cas 17557-84-5|| where to buy azetidin-3-one hydrochloride

Nom du produit:azetidin-3-one hydrochloride

IUPAC Name:azetidin-3-one hydrochloride

Unité d'emballage	Stock disponible	Prix($)
CM103679-25g	in stock	ŉŗ
CM103679-100g	in stock	Źŗǵ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 17557-84-5 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:17557-84-5; Formule moléculaire:C3H6ClNO; Point de fusion:-; Code SMILES:Cl.O=C1CNC1; Densité:

: Numéro de catalogue:CM103679; Poids moléculaire:107.54; Point d'ébullition:; N° Mdl:MFCD01861742; Stockage:

: Azetidines; Azetidines are an important class of saturated four-membered nitrogen-containing heterocyclic compounds. The research hotspots related to this structure mainly focus on two aspects: one is the research of pharmaceutical chemistry; the other is related to chiral azetidines, using rigid azetidine compounds as chiral ligands for asymmetric catalytic reactions. Many nitrogen-containing heterocycles play important roles in drug structures, and in many cases small structural changes can improve ligand selectivity and pharmacokinetic properties.; Where to buy Azetidines; Where to buy ADC-Cytotoxins? Chemenu Provide Azetidines with high quality and competitive price. Contact us Now.

: Alicyclic Heterocycles; When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.

: Palazestrant; Olema Oncology is advancing the development of Palazestrant (OP-1250) in metastatic breast cancer in 2024. Palazestrant is an oral complete ER antagonist (CERAN) and selective ER degrader (SERD). It potently binds and completely blocks transcriptional activity of both wild-type and ESR1-mutant ER with favorable tolerability and anti-tumor activity.
Palazestrant is under clinical development both in combination with Novartis' CDK4/6 inhibitor Kisqali (Ribociclib) as a first-line therapy for advanced estrogen receptor-positive, HER2-negative breast cancer, and as a monotherapy compared to standard of care treatment in second- and third-line advanced or metastatic ER-positive, HER2-negative breast cancer.